At present, the research and development of drugs that target the “do not eat me” signaling pathway is a hot topic in the new generation of tumor immunotherapy, with drugs that focus on the CD47-SIRPα axis show rapid progress in clinical development (Supplementary Table S1). This evidence concerns the gene SIRPA and neoplasm.